Motus GI Holdings, Inc. announced that the Pure-Vu EVS Gastro was successfully used in the first procedure since receiving FDA clearance. The case was completed by Dr. Brian Hanson, Gastroenterologist and Associate Professor of Medicine, University of Minnesota. Pure-Vu EVS irrigation jets - Caption: Pure-Vu EVS irrigation jets washing a biopsy site in the Upper GI tract: The Pure-Vu EVS Gastro, which received FDA clearance in late October 2023, opens the critically important upper gastrointestinal (GI) portion of the market and access to the high acuity patients that suffer from an upper GI bleeding where visualization to address this high mortality condition can be a significant issue.

The Pure-Vu EVS Gastro builds off the success of the patented and proprietary pulsed vortex irrigation and smart sense suction used in the colon device and has been enhanced to target blood, blood clots and other debris in the upper GI tract. Upper GI bleeds occurred in the U.S. at a rate of approximately 400,000 cases per year in 2019, according to iData Research Inc. The existence of blood and blood clots in these patients can impair a physician?s view, making it difficult to identify the bleed source. The Company believes removing adherent blood clots from the field of view is a significant need in allowing a physician the ability to identify and treat the bleed source.

The mortality rate of this condition can reach up to approximately 10%, as noted in Thad Wilkins, MD, et al., American Family Physician (2012).